Pfizer-BioNTech vaccine in patients undergoing cancer treatment

(JAMA Network)What The Study Did:The SARS-CoV-2 BNT162b2 (Pfizer-BioNTech) vaccineappeared to be safe and achieve satisfactory serologic status in patients with cancer. While therewas a lag in antibody production compared with the rate in the noncancer control group,seroconversion occurred in most patients after the second dose.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news